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Table 1
No serotherapy ATG Alemtuzumab p value
ADV 5.8 (0-16.9)% 0 % 29.3 (5.1-53.5)% 0.056
CMV 5.8 (0-16.9)% 20 (0-44.8)% 34 (9.7-58.3)% 0.08
EBV 5.8 (0-16.9)% 18.2 (0-40.5)% 0% .25
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Unrelated cord blood transplant (UCBT) is an established
graft source for HSCT especially for minorities. Use of sero-
therapy such as anti-thymocyte globulin (ATG) and alemtu-
zumab is associated with delayed immune reconstitution,
leading to increased viral reactivation especially when the
donors are virus naïve. Therefore, we studied the impact of
serotherapy along with other factors on viral reactivation
(EBV, CMV, adenovirus (ADV)), GVHD, and transplant-related
mortality (TRM) at 100 days in pediatric patients after UCBT.
Statistics used were chi-squared test, and Kaplan-Meier cu-
mulative incidence (CI) with log-rank. For CI of viral reac-
tivation, patients were censored if they died or reached day
100 before viral reactivation. All patients had weekly GVHD
grading using Glucksberg criteria and weekly PCR for the 3
viruses. Reactivation was deﬁned as blood viral PCR>1000
copies/ml. This retrospective study evaluated 47 consecutive
UCBTs performed from 2006-2014. Median age was 3 years
(range 0-17). Diagnoses: leukemia (19), immunodeﬁciency
(10), hemoglobinopathy (7), bone marrow failure (6), meta-
bolic disorder (3), andhistiocytic disorder (2). 21 patients
received myeloablative conditioning (MAC) and 26 reduced-
intensity conditioning (RIC). Median degree of HLA matching
was 5/6 (4-6/6). Pre-transplant serotherapy was used in 30
patients (15alemtuzumab, 15 ATG) irrespective of HLA
matching. Median cell dose was 6.15x107(0.9e18.9x107)
TNC/kg. Among all variables evaluated, underlying diagnosis
was the only one associated with development of  grade 2
acute GVHD, occurring predominantly in leukemia patients
(p¼0.048). For viral reactivation, the conditioning regimen
inﬂuenced CMV reactivation, with signiﬁcantly more CMV
reactivations in MAC recipients (p ¼ 0.044), and more EBV
reactivations in RIC recipients (p ¼ 0.046). Conditioning
regimen did not inﬂuence ADV reactivation. For ADV, only
the type of serotherapy had a strong association with reac-
tivation, with more ADV infections in patients who received
alemtuzumab (p ¼ 0.044). No variable had a relationship
with TRM. We then explored the day 100 CI of viral reac-
tivation, by type of serotherapy (Table 1). There was a trend
towards higher CI of ADV reactivation in patients who
received alemtuzumab. We conclude that in pediatric UCBT
patients, while the impact of serotherapy on acute GVHD is
unclear, it does have a major impact on viral reactivation.
Speciﬁcally, alemtuzumab appears to have more impact on
ADV reactivation than ATG. While further data will be
collected on the morbidity and mortality associated with
these infections, novel therapies to treat viruses in the
context of serotherapy-treated UCBT recipients are needed.283
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Objective: Inherited bone marrow failure syndromes
(IBMFS) are a heterogeneous group of genetic disorders
characterized by bone marrow failure, congenital anomalies,
and an increased risk of malignant disease. Because of
phenotypic variability, diagnosis can be challenging for cli-
nicians. This study is aimed to develop a targeted panel-
based Next Generation Sequencing (NGS) pipeline to clinical
diagnosis in IBMFS patients.
Method: Agilent Haloplex method was used for target cap-
ture the IBMFS Library of known genes and related genes,
Illumina platformwas used for high-throughput sequencing,
sequencing data was aligned by NextGENe software, the
variants were ﬁltered and interpretation by the online tool
Ingenuity Variant Analysis, and Sanger sequencing was used
to conﬁrm the variations. 21 patients with suspected IBMFS
were studied and DNA frommembers of each pedigree were
collected for this study.
Results: More than 95% of the sequencing reads aligned to
human genome reference sequence and more than 85% of
the reads are in the target sequence. The 20 coverage area is
>95% and the uniformity is >85%. Of the 21 patients with
suspected IBMFS, pathogenic mutations have been identiﬁed
in 12 patients, including 6 cases with Fanconi anemia (FA), 2
cases of Dyskeratosis congenital (DC), 2 cases of Severe
congenital neutropenia (SCN), 1 case of Diamond-Blackfan
anemia (DBA), and 1 case of Shwachman-Diamond syn-
drome (SDS). After hematopoietic stem cell transplantation,
5 patients were successfully cured. Prenatal diagnosis has
been successfully performed in 3 families.
Conclusion: This study successfully established the target
panel sequencingmethod tomoleculardiagnosis of IBMFS. The
clinical results showed that our method can effectively detect
and identify pathogenic genes in monogenic disorders and to
provide a strong basis for completely cure and prenatal diag-
nosis, because the efﬁciency of captured target region is
excellent, the quality of sequencing data is reliable, and the
analysis by the bioinformatics software is very comprehensive.284
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